Chew fly, don't bother meAugust 30, 2001Genetic engineering may offer new hope for controlling malaria, entomologists will tell the Royal Entomological Society's meeting Entomology 2001: "Insects and disease", to be held at the University of Aberdeen on 10-12 September 2001. Alex Schwartz of the University of Aarhus in Denmark, and Professor Jacob Koella of the Université Curie in Paris, will tell the meeting that genetic engineering could allow entomologists to make mosquitoes immune to the malaria parasite, so that they no longer pass the disease on to humans. Entomologists are working on identifying the gene responsible for immunity to malaria - termed "refractoriness" - in Anopheles gambiae, which they could then incorporate into mosquito populations. However, the spread of the gene through the mosquito population depends on whether there is a biological "cost" to the mosquito. According to Schwartz: "We are looking at what the mosquito gains and loses by being immune to malaria. Immunity will spread through the population only if the benefits outweigh the costs." For example, one benefit of immunity is that the mosquito would no longer be damaged by the malaria parasite. Another is that when infected by malaria, the parasite manipulates the mosquito to make it feed most only when the parasite is sufficiently developed to infect the human or animal that the mosquito bites. Schwartz says: "Our research in Tanzania indicates that simply harbouring the parasite can increase mortality of the mosquito, and our laboratory work shows that the parasite can manipulate the biting behaviour of the mosquito. The oocyst - or non-infective stage - of the malaria parasite prevents mosquitoes from blood feeding as much as they would if they were not infected. Thus, what can be seen as suicidal, kamikaze-like behaviour of the mosquito is beneficial to the parasite." One way that mosquitoes achieve immunity against malaria is to encapsulate - or "melanise" - the parasite. But Schwartz has found that melanisation can be costly to mosquitoes, as those with strong melanisation lay fewer eggs and develop more slowly: "Our results show that the mosquito's melanisation response is associated with benefits and costs that might limit the spread of immunity in malaria-control programmes based on genetic engineering," he says. Schwartz adds: "Our results emphasise the complexity involved in the evolutionary ecology of refractoriness. These aspects must be extensively studied, from the molecular level to natural populations, to understand and predict conditions under which genetic engineering can help reduce malaria transmission." A. gambiae's genome is currently being sequenced, and a draft copy of its genetic code will be complete early in 2002. This will make A. gambiae only the second insect (after Drosophila melanogaster) whose genome has been sequenced. Professor Frank Collins of Notre Dame University in the USA will be giving a progress report on the A. gambiae genome project to Entomology 2001 and will outline future research that will become possible once the mosquito's genome has been sequenced. New ways of controlling malaria are desperately needed as the malaria parasite becomes resistant to the drugs used to treat the disease, and A. gambiae (the major vector of malaria in Africa) develops resistance to insecticides. Half the world's population lives in malarious areas, and malaria kills two million people each year, most of them children living in sub-Saharan Africa. Professor Jacob Koella and Alex Schwartz will present their full findings at 15:40 on Tuesday 11 September and 16:00 on Wednesday 12 September 2001, respectively. Professor Frank Collins will present his paper at 13:00 on Monday 10 September 2001. Royal Entomological Society (RES) |
|||||||||||||||||||||
| Related Malaria Current Events and Malaria News Articles Measuring and modeling blood flow in malaria When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells. On the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites. Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease. Small nanoparticles bring big improvement to medical imaging If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging. Prioritizing low-cost, simple health measures would save 2.5 million child lives a year Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. DNA barcodes: Creative new uses span health, fraud, smuggling, history, more The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. More Malaria Current Events and Malaria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||